Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1989 5
1990 1
1992 3
1993 1
1994 1
1996 1
1998 2
1999 3
2000 5
2001 1
2002 3
2003 3
2004 3
2005 5
2006 3
2007 5
2008 15
2009 4
2010 5
2011 1
2012 3
2013 5
2014 13
2015 13
2016 11
2017 7
2018 9
2019 3
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Rodger AJ, et al. Among authors: blaxhult a. Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2. Lancet. 2019. PMID: 31056293 Free PMC article.
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group. Rodger AJ, et al. JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. JAMA. 2016. PMID: 27404185 Free article.
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
Gaines H, Albert J, Axelsson M, Berglund T, Gisslén M, Sönnerborg A, Blaxhult A, Bogdanovic G, Brytting M, Carlander C, Flamholc L, Follin P, Haggar A, Hagstam P, Johansson M, Navér L, Persson Blom J, Samuelson A, Ström H, Sundqvist M, Svedhem Johansson V, Tegmark Wisell K, Tegnell A, Thorstensson R. Gaines H, et al. Among authors: blaxhult a. Infect Dis (Lond). 2016 Feb;48(2):93-8. doi: 10.3109/23744235.2015.1089593. Epub 2015 Sep 28. Infect Dis (Lond). 2016. PMID: 26414596 Review.
Treatment as prevention for HIV: a reality.
Blaxhult A, Bratt G. Blaxhult A, et al. AIDS. 2015 Aug 24;29(13):1721. doi: 10.1097/QAD.0000000000000759. AIDS. 2015. PMID: 26372285 No abstract available.
Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
Albert J, Berglund T, Gisslén M, Gröön P, Sönnerborg A, Tegnell A, Alexandersson A, Berggren I, Blaxhult A, Brytting M, Carlander C, Carlson J, Flamholc L, Follin P, Haggar A, Hansdotter F, Josephson F, Karlström O, Liljeros F, Navér L, Pettersson K, Johansson VS, Svennerholm B, Tunbäck P, Widgren K. Albert J, et al. Among authors: blaxhult a. Scand J Infect Dis. 2014 Oct;46(10):673-7. doi: 10.3109/00365548.2014.926565. Epub 2014 Jul 30. Scand J Infect Dis. 2014. PMID: 25073537 Free PMC article. Review.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Orkin C, et al. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993180 Clinical Trial.
126 results